Literature DB >> 4156313

The urinary excretion profile of naltrexone and metabolites in man.

E J Cone, C W Gorodetzky, S Y Yeh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4156313

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


× No keyword cloud information.
  6 in total

1.  Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.

Authors:  Linda Olsen; Asbjørg S Christophersen; Grete Frogopsahl; Helge Waal; Jørg Mørland
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

Authors:  R E Bullingham; H J McQuay; R A Moore
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

3.  Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.

Authors:  S J Porter; A A Somogyi; J M White
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 4.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 5.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

6.  Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.

Authors:  Gantt P Galloway; Monika Koch; Ryan Cello; David E Smith
Journal:  BMC Psychiatry       Date:  2005-04-01       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.